Regeneron (REGN) Downgraded by UBS

Regeneron (NASDAQ:REGN) was downgraded by investment analysts at UBS from an “outperform” rating to a “market perform” rating in a note issued to investors on Monday, The Fly reports.

A number of other research analysts have also weighed in on REGN. Robert W. Baird raised Regeneron from a “neutral” rating to an “outperform” rating in a report on Friday, February 9th. They noted that the move was a valuation call. Deutsche Bank set a $367.00 price objective on Regeneron and gave the stock a “hold” rating in a report on Tuesday, March 13th. SunTrust Banks set a $430.00 price objective on Regeneron and gave the stock a “hold” rating in a report on Friday, February 9th. BidaskClub raised Regeneron from a “sell” rating to a “hold” rating in a report on Thursday, March 29th. Finally, BTIG Research reissued a “hold” rating on shares of Regeneron in a report on Tuesday, March 13th. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $449.49.

How to Become a New Pot Stock Millionaire

REGN stock opened at $319.61 on Monday. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11. The stock has a market cap of $34,420.71, a price-to-earnings ratio of 23.83, a P/E/G ratio of 1.04 and a beta of 1.45. Regeneron has a twelve month low of $313.53 and a twelve month high of $543.55.

Regeneron (NASDAQ:REGN) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.18 by $1.05. The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.50 billion. Regeneron had a return on equity of 28.48% and a net margin of 20.41%. The company’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.04 EPS. sell-side analysts expect that Regeneron will post 19.2 EPS for the current fiscal year.

In other Regeneron news, Director Joseph L. Goldstein sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $340.00, for a total value of $680,000.00. Following the completion of the sale, the director now owns 14,000 shares of the company’s stock, valued at $4,760,000. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,000 shares of company stock valued at $1,705,640. 10.80% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Polen Capital Management LLC boosted its stake in Regeneron by 1.2% in the fourth quarter. Polen Capital Management LLC now owns 1,389,545 shares of the biopharmaceutical company’s stock worth $522,413,000 after buying an additional 15,931 shares in the last quarter. Geode Capital Management LLC boosted its stake in Regeneron by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 880,481 shares of the biopharmaceutical company’s stock worth $330,385,000 after buying an additional 30,581 shares in the last quarter. Franklin Resources Inc. boosted its stake in Regeneron by 4.5% in the fourth quarter. Franklin Resources Inc. now owns 819,796 shares of the biopharmaceutical company’s stock worth $308,212,000 after buying an additional 35,123 shares in the last quarter. Clearbridge Investments LLC boosted its stake in Regeneron by 6.2% in the fourth quarter. Clearbridge Investments LLC now owns 806,762 shares of the biopharmaceutical company’s stock worth $303,310,000 after buying an additional 47,010 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Regeneron by 516.8% in the fourth quarter. Renaissance Technologies LLC now owns 579,562 shares of the biopharmaceutical company’s stock worth $217,892,000 after buying an additional 485,600 shares in the last quarter. 66.39% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This article was published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3343116/regeneron-regn-downgraded-by-ubs.html.

Regeneron Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

The Fly

Analyst Recommendations for Regeneron (NASDAQ:REGN)

Receive News & Ratings for Regeneron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Reata Pharmaceuticals  Raised to “Sell” at BidaskClub
Reata Pharmaceuticals Raised to “Sell” at BidaskClub
Territorial Bancorp  Stock Rating Lowered by BidaskClub
Territorial Bancorp Stock Rating Lowered by BidaskClub
VSE  Upgraded at BidaskClub
VSE Upgraded at BidaskClub
Credit Suisse Group Raises Snap  Price Target to $21.00
Credit Suisse Group Raises Snap Price Target to $21.00
Zacks Investment Research Lowers NVR  to Sell
Zacks Investment Research Lowers NVR to Sell
Bristol-Myers Squibb’s  Hold Rating Reiterated at Cowen
Bristol-Myers Squibb’s Hold Rating Reiterated at Cowen


Leave a Reply

© 2006-2018 Ticker Report. Google+.